Session: Advancing Knowledge in Diabetes
The prevalence of Diabetes in Europe has grown to an alarming 10% of adults. Breakthroughs in Diabetes care are urgently needed. ESMED Congress 2021 will examine the latest technologies and ideas for Diabetes care.
Chaired by Philippe Valet, Ph.D., INSERM
Dysregulation of Leptin and Testosterone Production and Their Receptor Expression in the Human Placenta with Gestational Diabetes Mellitus
Zhenmin Lei, University of Louisville School of Medicine
My laboratory has engaged in the research of reproductive endocrinology for many years. The focus of the research in my laboratory involves understanding the molecular mechanism of gonadotropins and sex steroid hormones that regulate the development and function of gonadal and non-gonadal tissues as well as the roles in tumorigenesis and therapy. To this end, we successfully established numerous techniques that are essential for study in this field, including transgenic and gene knockout mouse models and cell-based assays. As PI or co-Investigator on several previous NIH- and state-funded grants, I am experienced in constructing a realistic plan, timeline and budget as well as research training. I have a demonstrated record of successful and productive research projects in an area that is highly relevant to endocrine work.
Predicting hospital readmission risk of people with diabetes
Daniel Rubin, Temple University
Hospital readmissions are a costly and undesirable outcome. Given the global prevalence of diabetes and the increased risk of readmission associated with diabetes, people with diabetes suffer a huge burden of readmissions. An understanding of readmission risk is critical to optimize the efficiency of interventions for reducing this risk. Qualitative and quantitative studies have described numerous sources of readmission risk, including health system failure, poor health literacy, social determinants of health, diabetes features, comorbidities, hospital factors, and abnormal laboratory results. Tools designed to predict the readmission risk of individual patients have been developed. One such tool specifically designed for people with diabetes is the Diabetes Early Readmission Risk Indicator (DERRI TM), which has been internally and externally validated. Adding variables to the DERRI TM improves predictive accuracy but decreases the feasibility of use at the point of care. We are working on embedding this tool in an electronic health record system to allow for more complex and accurate models while increasing the feasibility of obtaining readmission risk predictions in routine clinical practice. Using tools like the DERRI TM to identify patients at high risk of readmission enables the targeting of resources for reducing the risk of patients most in need.
Adipose-derived Stromal Vascular Fraction (SVF) cells: Treatment of Critical-Size Defects in Diabetes
Michael Carstens, Wake Forest University Institute of Regenerative Medicine
Apelin, a new path of worthwhile investigation in the treatment of diabetes?
Philippe Valet, Ph.D., INSERM
Choline treatment affects the liver reticuloendothelial system and plasma fatty acid composition in diabetic rats
Fatma Al-Saeedi, Kuwait University
This study investigated effects of choline treatment on hepatic reticuloendothelial
and biliary functions and plasma fatty acid composition in diabetic rats.
Methods: Diabetes was induced by streptozotocin (STZ). Choline was administered
to untreated rats and a portion of STZ-treated rats for two sequences of five consecutive
days, separated by a 2-day interval. Hepatic functions were studied using
99mTc Tin (II) colloid (TIN) and 99 mTc mebrofenin [bromo-iminodiacetic acid
(BrIDA)] imaging. The TIN-uptake ratios (organ/whole body) of heart, liver and
spleen, and the BrIDA-uptake ratios (organ or tissue/whole body) of liver, biliary
tree and abdomen were obtained following imaging studies. Fatty acids were
analysed by GC/MS.